(Q73251638)

English

Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group

scientific article published on 01 December 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

multiple sclerosis

1 reference

based on heuristic

inferred from title

author name string

C Liu

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

L D Blumhardt

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 December 2000

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Journal of the Neurological Sciences

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

181

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1-2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

33-37

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Clinical outcome measures and rating scales in multiple sclerosis trials

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Analysis of serial measurements in medical research

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Scales for rating impairment in multiple sclerosis: a critique.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Clinical scales for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

The psychometric properties of clinical rating scales used in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Kurtzke scales revisited: the application of psychometric methods to clinical intuition

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Randomised, double blind, placebo controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

"Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2800%2900401-9

7 January 2021

Identifiers

10.1016/S0022-510X(00)00401-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11099709%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73251638&oldid=1910784492"